SciSparc announces results from weight loss, metabolic disorder program

SciSparc (SPRC) announced successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem. The trial was conducted as part of the collaboration between SciSparc and Clearmind Medicine (CMND). The combination treatment includes palmitoylethanolamide, an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression. The goal of the trial was to identify the optimal dosage for the Combination Treatment and, in turn, observe the safety and impact thereof on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Results indicated: The administered treatment exhibited a meaningful degree of tolerance, leaving the mice’s viability unaffected across all experimental groups. Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. The changed rates of oxygen consumption and carbon dioxide emission indicate increases in the metabolic process and fat burn. A notable reduction in food consumption and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted particularly at 20 and 10 mg/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity. “I am encouraged by the positive results from our recent pre-clinical trial, which represents another milestone in our ongoing efforts to develop safe and effective innovative therapies. The successful collaboration between SciSparc and Clearmind continues to demonstrate the potential of our Combination Treatment to address obesity and related health challenges,” said Oz Adler, SciSparc’s Chief Executive Officer. “The trial’s findings, including increased metabolic activity, reduced appetite, and enhanced fat oxidation, are promising indicators of the treatment’s efficacy and safety.”